Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1956 1
1957 4
1958 7
1959 1
1960 3
1961 2
1962 6
1963 6
1964 9
1965 7
1966 17
1967 14
1968 18
1969 11
1970 13
1971 25
1972 11
1973 15
1974 15
1975 25
1976 28
1977 24
1978 24
1979 25
1980 24
1981 47
1982 45
1983 56
1984 62
1985 64
1986 67
1987 82
1988 66
1989 96
1990 95
1991 86
1992 127
1993 101
1994 113
1995 113
1996 112
1997 124
1998 149
1999 155
2000 179
2001 193
2002 173
2003 193
2004 214
2005 190
2006 201
2007 228
2008 240
2009 254
2010 264
2011 298
2012 297
2013 356
2014 345
2015 323
2016 352
2017 373
2018 384
2019 340
2020 374
2021 440
2022 458
2023 398
2024 146

Text availability

Article attribute

Article type

Publication date

Search Results

8,408 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. Among authors: inoue y. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. Among authors: inoue y. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. Travis WD, et al. Among authors: inoue y. Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST. Am J Respir Crit Care Med. 2013. PMID: 24032382 Free PMC article.
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
Dauvilliers Y, Mignot E, Del Río Villegas R, Du Y, Hanson E, Inoue Y, Kadali H, Koundourakis E, Meyer S, Rogers R, Scammell TE, Sheikh SI, Swick T, Szakács Z, von Rosenstiel P, Wu J, Zeitz H, Murthy NV, Plazzi G, von Hehn C. Dauvilliers Y, et al. Among authors: inoue y. N Engl J Med. 2023 Jul 27;389(4):309-321. doi: 10.1056/NEJMoa2301940. N Engl J Med. 2023. PMID: 37494485 Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Among authors: inoue y. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease.
Liu CC, Wang N, Chen Y, Inoue Y, Shue F, Ren Y, Wang M, Qiao W, Ikezu TC, Li Z, Zhao J, Martens Y, Doss SV, Rosenberg CL, Jeevaratnam S, Jia L, Raulin AC, Qi F, Zhu Y, Alnobani A, Knight J, Chen Y, Linares C, Kurti A, Fryer JD, Zhang B, Wu LJ, Kim BYS, Bu G. Liu CC, et al. Among authors: inoue y. Nat Immunol. 2023 Nov;24(11):1854-1866. doi: 10.1038/s41590-023-01640-9. Epub 2023 Oct 19. Nat Immunol. 2023. PMID: 37857825
A predictive model for acute exacerbation of idiopathic interstitial pneumonias.
Karayama M, Aoshima Y, Suzuki T, Mori K, Yoshizawa N, Ichikawa S, Kato S, Yokomura K, Kono M, Hashimoto D, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Goshima S, Inui N, Suda T. Karayama M, et al. Among authors: inoue y. Eur Respir J. 2023 May 5;61(5):2201634. doi: 10.1183/13993003.01634-2022. Print 2023 May. Eur Respir J. 2023. PMID: 36822633 Free PMC article.
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.
Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T, Baldwin M, Mueller H, Rohr KB, Flaherty KR; INBUILD Trial Investigators. Wijsenbeek M, et al. Among authors: inoue y. Eur Respir J. 2024 Feb 1;63(2):2300752. doi: 10.1183/13993003.00752-2023. Print 2024 Feb. Eur Respir J. 2024. PMID: 38135442 Free PMC article. Clinical Trial.
8,408 results